5. Total revenues and other income

REVENUES

The following table summarizes the revenues for the years ended December 31, 2018, 2017 and 2016.


	Year ended December 31,
	2018		2017		2016
		(Euro, in thousands)
Recognition of non-refundable upfront payments and license fees	€	196,487	€	71,971	€	30,257
Milestone payments		73,394		42,950		81,784
Reimbursement income		8,722		3,273		9,699
Other revenues		10,233		8,893		7,777
Total revenues	€	288,836	€	127,087	€	129,519

For the years ended December 31, 2018 and 2017

The following table summarizes the revenue recognition of upfront payments, license fees and milestone payments for the years ended December 31, 2018 and 2017, as well as the impact of the adoption of IFRS 15. The revenues recognized for the years ended December 31, 2018 presented under the IFRS 15 standard as well as under the former applicable IAS 18 standard, with a comparison to the year ended December 31, 2017 under the former applicable IAS 18 standard.


							IAS 18				IFRS 15		IFRS 15		IAS 18		IAS 18		IFRS 15
							Outstanding		Deferred		Outstanding								Outstanding
							balance in		income		balance in		Revenue		Revenue		Revenue		balance in
							deferred		reclassified		deferred		recognized,		recognized,		recognized,		deferred
							income as at		from equity		income as at		year ended		year ended		year ended		income as at
						Collaboration	December 31,		following adoption		January 1,		December 31,		December 31,		December 31,		December 31,
Agreement	Consideration		Consideration			start date	2017		of IFRS 15		2018		2018		2018		2017		2018
	(USD, in thousands)		(Euro, in thousands)										(Euro, in thousands)
Revenue recognition of considerations received prior to December 31, 2017
Gilead collaboration agreement for filgotinib - Upfront payment	$	300,000	€	275,558		January 2016	€	187,449			€	187,449	€	84,806	€	84,806	€	62,488	€	102,643
Gilead collaboration agreement for filgotinib - Subscription agreement (*)		N.A.	€	39,003	(*)	January 2016	€	26,532			€	26,532	€	12,004	€	12,004	€	8,845	€	14,528
Servier collaboration agreement for osteoarthritis - License fee		N.A.	€	6,000		June 2010	€	5,362	€	(5,362)	€	—	€	—	€	1,532	€	638	€	—
AbbVie collaboration agreement for CF - Upfront payments	$	45,000	€	34,001		September 2013	€		€	14,872	€	14,872	€	14,140	€	—	€	—	€	732
Total upfront payments and license fees:							€	219,343	€	9,510	€	228,853	€	110,950	€	98,342	€	71,971	€	117,903

Gilead collaboration agreement for filgotinib - Milestone payments	$	70,000	€	64,435		January 2016			€	43,832	€	43,832	€	19,831	€	—	€	9,354	€	24,001
AbbVie collaboration agreement for CF - Milestone payments	$	77,500	€	68,310		September 2013			€	29,878	€	29,878	€	28,406	€	—	€	33,596	€	1,471
Total milestones:									€	73,710	€	73,710	€	48,237	€	—	€	42,950	€	25,472
Total :							€	219,343	€	83,220	€	302,563	€	159,187	€	98,342	€	114,921	€	143,375

Revenue recognition of considerations in the year ended December 31, 2018
Novartis collaboration agreement for MOR106 - Upfront payment		N.A.	€	47,500		September 2018							€	47,500	€	47,500			€	—
AbbVie collaboration agreement for CF - Upfront payment	$	45,000	€	38,874		September 2013							€	38,037	€	38,037			€	837
Total upfront payments and license fees:													€	85,537	€	85,537			€	837
Gilead collaboration agreement for filgotinib - Milestone payments	$	15,000	€	12,418		January 2016							€	7,793	€	12,418			€	4,625
AbbVie collaboration agreement for CF - Milestone payments	$	10,000	€	8,548		September 2013							€	8,364	€	8,548			€	184
Servier collaboration agreement for osteoarthritis - Milestone payment		N.A.	€	9,000		June 2010							€	9,000	€	9,000			€	—
Total milestones:													€	25,157	€	29,966			€	4,809
Total :													€	110,694	€	115,503			€	5,646
Grand total : upfront payments and license fees and milestones													€	269,881	€	213,845			€	149,021

(*) deferred income of €39 million booked upon signing of the share subscription agreement with Gilead as required under IAS 39



	IFRS 15				IAS 18
	Over time	Point in time		2018			2017	Over time	Point in time
				(Euro, in			(Euro, in
				thousands)			thousands)
Recognition of non-refundable upfront payments and license fees			€	196,486		€	71,971
Gilead collaboration agreement for filgotinib				96,809			71,333	
AbbVie collaboration agreement for CF				52,176			-	
Novartis collaboration agreement for MOR106				47,500			-		
Servier collaboration agreement for osteoarthritis				-			638	

Milestone payments				73,394			42,950
Gilead collaboration agreement for filgotinib				27,623			9,354		
AbbVie collaboration agreement for CF				36,771			33,596		
Servier collaboration agreement for osteoarthritis				9,000			-		

Reimbursement income				8,722			3,273
Novartis collaboration agreement for MOR106				7,718			-
AbbVie collaboration agreement for CF				989			453		
Servier collaboration agreement for osteoarthritis				-			2,816		
Other reimbursement income				16			4

Other revenues				10,233			8,893
Fee-for-services revenues				10,170			8,825	
Other revenues				63			68
Total revenues			€	288,836		€	127,087

For the years ended December 31, 2017 and 2016

The following table summarizes the upfront payments recognition for years ended December 31, 2017 and 2016 under IAS 18.


Agreement	Upfront received		Upfront and license fees received			Recognition as from	Revenue recognized, year ended December 31, 2017		Revenue recognized, year ended December 31, 2016		Outstanding balance in deferred income as at December 31, 2017
	(USD, in thousands)		(Euro, in thousands)				(Euro, in thousands)
Gilead collaboration agreement for filgotinib	$	300,000	€	275,558		January 2016	€	62,488	€	25,621	€	187,449
Gilead collaboration agreement for filgotinib		N.A.	€	39,003	(*)	January 2016	€	8,845	€	3,626	€	26,532
ThromboGenics license agreement for integrin antagonists		N.A.	€	1,000		April 2016	€	—	€	1,000	€	—
Sirion Biotech license agreement for RNA interference (RNAi) technologies		N.A.	€	10		June 2016	€	—	€	10	€	—
Servier collaboration agreement for osteoarthritis		N.A.	€	6,000		August 2017	€	638	€	—	€	5,362
Total recognition of non-refundable upfront payments and license fees							€	71,971	€	30,257	€	219,343

(*)deferred income of €39 million booked upon signing of the share subscription agreement with Gilead as required under IAS 39—Financial Instruments: recognition and measurement

OTHER INCOME

The following table summarizes other income for the years ended December 31, 2018, 2017 and 2016.


	Year ended December 31,
	2018		2017		2016
		(Euro, in thousands)
Grant income	€	1,609	€	1,045	€	2,329
Other income		27,400		27,785		19,764
Total other income	€	29,009	€	28,830	€	22,093